AI Article Synopsis
Article Abstract
Longer-than-annual screening intervals have been suggested to improve the balance of benefits and harms in prostate cancer screening. Many researchers, societies, and guideline committees have suggested that screening intervals could depend on the prostate-specific antigen (PSA) result. We analyzed data from men ( = 33,897) ages 55-74 years with a baseline PSA test in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial (United States, 1993-2001). We estimated 5- and 10-year risks of aggressive cancer (Gleason ≥8 and/or stage III/IV) and 15-year risks of prostate cancer-related mortality for men with baseline PSA ≤ 0.5 ng/mL ( = 4,862), ≤1 ng/mL ( = 15,110), and 1.01-2.5 ng/mL ( = 12,422). A total of 217 men died from prostate cancer through 15 years, although no men with PSA ≤ 1 ng/mL died from prostate cancer within 5 years [95% confidence interval (CI), 0.00%-0.03%]. The 5-year incidence of aggressive disease was low (0.08%; 95% CI, 0.03%-0.12%) for men with PSA ≤ 1 ng/mL, and higher for men with baseline PSA 1.01-2.5 ng/mL (0.51%; 95% CI, 0.38%-0.74%). No men aged ≥65 years with PSA ≤ 0.5 ng/mL died from prostate cancer within 15 years (95% CI, 0.00%-0.32%), and their 10-year incidence of aggressive disease was low (0.25%; 95% CI, 0.00%-0.53%). Compared with white men, black men with PSA ≤ 1 ng/mL had higher 10-year rates of aggressive disease (1.6% vs. 0.4%; < 0.01). Five-year screening intervals may be appropriate for the 45% of men with PSA ≤ 1 ng/mL. Men ages ≥65 years with PSA ≤ 0.5 ng/mL could consider stopping screening. Substantial risk disparities suggest appropriate screening intervals could depend on race/ethnicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339970 | PMC |
| http://dx.doi.org/10.1158/1940-6207.CAPR-19-0397 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide.
Clin Genitourin Cancer
November 2024
Medical Oncology, Santa Chiara Hospital, Trento, Italy.
Introduction: Over the years, several prognostic models were developed in patients receiving chemotherapy for metastatic castration resistant prostate cancer (mCRPC), while data on androgen-receptor signaling inhibitors (ARSI) in a real-world setting are limited.
Patients And Methods: We compared a consecutive series of 565 mCRPC patients receiving first-line ARSI at 4 high-volume Italian Centers (development set) to an external series of 180 patients receiving the same treatment at another Italian high-volume Center (training set), between 2011 and 2022. Sixteen clinical and baseline laboratory variables were selected to develop a prognostic model.
Matched-pair analysis of mCRPC patients receiving Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.
EJNMMI Res
October 2024
Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Article Synopsis
- A study was conducted to evaluate the effects of 4-week vs. 6-week treatment intervals for Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
- The results showed that the 4-week interval led to a higher PSA response (47.8% vs. 21.7%) and longer PSA-progression-free survival (26.0 weeks vs. 18.0 weeks), but the overall survival rates were not significantly different (15.1 months vs. 18.4 months).
- The 4-week treatment increased the risk of blood count reductions compared to the 6-week interval, suggesting a need for more research to
Bicenter validation of a risk model for the preoperative prediction of extraprostatic extension of localized prostate cancer combining clinical and multiparametric MRI parameters.
World J Urol
September 2024
Department of Urology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.
Article Synopsis
- This study validated a risk model that integrates clinical and multiparametric MRI parameters to predict extraprostatic extension (EPE) of prostate cancer before radical prostatectomy.
- The research analyzed data from 205 patients across two German hospitals, using techniques like receiver operating characteristic analysis to assess the model's effectiveness against ESUR criteria.
- Results showed the risk model had strong predictive performance (AUC = 0.86) for EPE, similar to the ESUR classification (AUC = 0.87), although its applicability may be limited to populations with a high prevalence of EPE.
Early treatment response assessment with [Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.
Cancer Imaging
September 2024
Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Article Synopsis
- The study aimed to compare interim PSMA-PET imaging with post-treatment whole-body scans (WBS) in monitoring treatment response for men with metastasized castration-resistant prostate cancer (mCRPC) undergoing radioligand therapy (RLT).
- Researchers included 188 men and found a strong correlation between responses measured by the two imaging methods, indicating that both affect overall survival (OS) outcomes significantly.
- Results suggested that early treatment responses, particularly a PSA decline of 50% after two cycles, were associated with improved survival probabilities, highlighting the importance of interim imaging in therapy monitoring.
Sequential [Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.
Lancet Oncol
October 2024
Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Article Synopsis
- Lutetium-177 [Lu]Lu-PSMA-617 is being studied for its effectiveness in improving survival and quality of life for patients with metastatic castration-resistant prostate cancer, but its benefits for hormone-sensitive prostate cancer are still unclear.
- The UpFrontPSMA trial involved patients with high-volume metastatic hormone-sensitive prostate cancer, who were randomly assigned to receive either [Lu]Lu-PSMA-617 followed by docetaxel or docetaxel alone as standard care.
- The primary goal of the trial was to determine if patients treated with [Lu]Lu-PSMA-617 could achieve undetectable levels of prostate-specific antigen (PSA) after 48 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!